Two Coronavirus Vaccines Enter Final Stages of Clinical Trials

Translate to Spanish or other 102 languages!

Mega Doctor News

- Advertisement -

As communities across the country consider whether to reopen schools and offices this fall, leaders are pinning their hopes to a COVID-19 vaccine that will soon be available.

The Chamber’s latest interactive map breaks down where clinical trials for COVID-19 vaccines and therapeutics are happening in the United States. There are currently 25 vaccines in the clinical stage of development, and just yesterday two entered the final stages.

Moderna began a Phase 3, 30,000-person trial for its leading vaccine candidate, developed in partnership with the National Institute of Allergy and Infectious Diseases. A day ahead of the beginning of the trial, the U.S. government threw additional support behind Moderna’s vaccine, committing an additional $472 million to the Phase 3 trial.

- Advertisement -

Late Monday afternoon, Pfizer and BioNTech announced the start of a global Phase 2/3 30,000-person safety and efficacy clinical trial for their leading mRNA vaccine candidate. If the vaccine candidate proves effective, the companies plan to seek regulatory approval as early as October 2020, with the goal of providing up to 100 million doses globally by the end of the year.

The story of these three innovative companies sheds light on the risk required to invest in innovative, life-saving treatments. To date, there has not yet been a successful mRNA vaccine developed. Should either the Moderna or Pfizer and BioNTech vaccine candidates prove successful, it would be an unprecedented breakthrough.

As these companies work at warp speed alongside other biopharmaceutical companies with vaccines in clinical development, the scientific community recognizes that an effective vaccine cannot come quickly enough. 

With our brightest scientific minds, the most innovative companies, and the nation’s leading universities on the task, the Chamber is confident that we will have an effective vaccine to help lead the global community out of this crisis soon. 

- Advertisement -

–Jonathan Weinberger, Executive Vice President, U.S. Chamber Global Innovation Policy Center

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Recognizes November as “National Hospice and Palliative Care” Month

DHR Health is pleased to recognize November as “National Hospice and Palliative Care Month.”  As we highlight National Hospice and Palliative Care Month, let us remember that healthcare is not solely about treating diseases but also about care for people at end of life.

STHS Heart Earns Healthgrades Five-Star Rating for Pacemaker Procedures

Healthgrades, the leading online resource for information about physicians and hospitals, has named STHS Heart a Five-Star Recipient for Pacemaker Procedures in 2027 for the second consecutive year, recognizing the facility's superior clinical outcomes and commitment to patient care.

Renaissance Cancer Foundation to Host 16th Anniversary “Viva la Vida” Gala, Nov. 21st

 The Renaissance Cancer Foundation, a non-profit organization of DHR Health, is excited to announce its 16th anniversary gala, featuring Miami’s premier party band, Extasy. The fundraising event is set to take place on November 21, 2026, at the Edinburg Conference Center at Renaissance, located at 118 Paseo Del Prado in Edinburg.

STHS Facilities Earn Healthgrades Five-Star Rating for Defibrillator Procedures

The human heart beats approximately 100,000 times each day, relying on a complex electrical system to maintain a steady rhythm.
- Advertisement -